Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

1E8X

STRUCTURAL INSIGHTS INTO PHOSHOINOSITIDE 3-KINASE ENZYMATIC MECHANISM AND SIGNALLING

Replaces:  1QMM
Summary for 1E8X
Entry DOI10.2210/pdb1e8x/pdb
Related1E7U 1E7V 1E8W 1QMM
DescriptorPHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT, ADENOSINE-5'-TRIPHOSPHATE, LUTETIUM (III) ION, ... (4 entities in total)
Functional Keywordsphosphoinositide 3-kinase gamma, secondary messenger generation, pi3k, pi 3k
Biological sourceSUS SCROFA (WILD BOAR)
Total number of polymer chains1
Total formula weight112034.44
Authors
Walker, E.H.,Perisic, O.,Ried, C.,Stephens, L.,Williams, R.L. (deposition date: 2000-10-03, release date: 2000-10-26, Last modification date: 2024-05-08)
Primary citationWalker, E.H.,Pacold, M.E.,Perisic, O.,Stephens, L.,Hawkins, P.T.,Whymann, M.P.,Williams, R.L.
Structural Determinations of Phosphoinositide 3-Kinase Inhibition by Wortmannin, Ly294002, Quercetin, Myricetin and Staurosporine
Mol.Cell, 6:909-, 2000
Cited by
PubMed Abstract: The specific phosphoinositide 3-kinase (PI3K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways. The X-ray crystallographic structures of PI3Kgamma bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compounds fit into the ATP binding pocket. With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain. Surprisingly, LY294002 and the lead compound on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind PI3K in remarkably different orientations that are related to each other by 180 degrees rotations. Staurosporine/PI3K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes. These results provide a rich basis for development of isoform-specific PI3K inhibitors with therapeutic potential.
PubMed: 11090628
DOI: 10.1016/S1097-2765(05)00089-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.2 Å)
Structure validation

227111

數據於2024-11-06公開中

PDB statisticsPDBj update infoContact PDBjnumon